Louise S Rasmussen1, Claus W Fristrup2, Benny V Jensen3, Per Pfeiffer4, Britta Weber5, Mette K Yilmaz6, Laurids Ø Poulsen7, Morten Ladekarl7, Kell Østerlind8, Jim S Larsen9, Hella Skuladottir10, Carsten P Hansen11, Michael B Mortensen12, Frank V Mortensen13, Mogens Sall14, Sönke Detlefsen15, Martin Bøgsted16, Ursula G Falkmer7. 1. Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark. Electronic address: loskr@rn.dk. 2. Danish Pancreatic Cancer Database, Denmark; Department of Surgery, Odense University Hospital, Odense, Denmark. 3. Department of Oncology, University Hospital Herlev, Herlev, Denmark. 4. Department of Oncology, Odense University Hospital, Odense, Denmark. 5. Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. 6. Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. 7. Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark. 8. Department of Oncology, North Zealand Hospital, Hillerød, Denmark. 9. Department of Oncology, Zealand University Hospital, Næstved and Roskilde, Denmark. 10. Department of Oncology, Herning Hospital, Herning, Denmark. 11. Department of Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 12. Odense Pancreas Center (OPAC), Department of Surgery, Odense University Hospital, Odense, Denmark. 13. Department of Surgical Gastroenterology, Aarhus University Hospital, Aarhus, Denmark. 14. Department of Surgical Gastroenterology, Aalborg University Hospital, Aalborg, Denmark. 15. Odense Pancreas Center (OPAC), Department of Pathology, Odense University Hospital, Odense, Denmark. 16. Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark; Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Abstract
BACKGROUND: Nationwide register data on the effect of primary treatment on survival in an unselected population of patients with pancreatic cancer (PC) have not been reported before. The study aim was to investigate the overall survival (OS) related to initial treatment with resection, chemotherapy, or best supportive care (BSC) in all patients diagnosed with PC in Denmark from 2011 to 2016. METHODS: From 1 May 2011 to 30 April 2016, 4260 patients with PC were identified in the Danish Pancreatic Cancer Database. Ninety-seven patients (2%) were excluded, 56 because of treatment with preoperative chemotherapy, 39 because of incorrect registration of diagnosis or treatment, and 2 because of loss to follow-up; thus, 4163 patients were included. RESULTS: The 718 patients (17%) receiving resection had a median overall survival (mOS) of 21.9 months (range 20.0-24.2). In the chemotherapy group of 1746 patients (42%), those treated with FOLFIRINOX had the longest mOS of 10.0 months (9.2-11.0), whereas those treated with gemcitabine had the shortest mOS of 5.1 months (4.8-5.6). The 1697 patients (41%) receiving BSC had a mOS of only 1.6 months (1.5-1.7). CONCLUSIONS: The resected PC cohort had an OS comparable with that reported in randomised controlled trials (RCTs). The mOS of the chemotherapy-treated patients was slightly shorter compared with the results from RCTs and reflects the unselected population in this study. During the last decade, a larger fraction of patients received anticancer treatment, but the BSC group was still large and showed extremely poor OS.
BACKGROUND: Nationwide register data on the effect of primary treatment on survival in an unselected population of patients with pancreatic cancer (PC) have not been reported before. The study aim was to investigate the overall survival (OS) related to initial treatment with resection, chemotherapy, or best supportive care (BSC) in all patients diagnosed with PC in Denmark from 2011 to 2016. METHODS: From 1 May 2011 to 30 April 2016, 4260 patients with PC were identified in the Danish Pancreatic Cancer Database. Ninety-seven patients (2%) were excluded, 56 because of treatment with preoperative chemotherapy, 39 because of incorrect registration of diagnosis or treatment, and 2 because of loss to follow-up; thus, 4163 patients were included. RESULTS: The 718 patients (17%) receiving resection had a median overall survival (mOS) of 21.9 months (range 20.0-24.2). In the chemotherapy group of 1746 patients (42%), those treated with FOLFIRINOX had the longest mOS of 10.0 months (9.2-11.0), whereas those treated with gemcitabine had the shortest mOS of 5.1 months (4.8-5.6). The 1697 patients (41%) receiving BSC had a mOS of only 1.6 months (1.5-1.7). CONCLUSIONS: The resected PC cohort had an OS comparable with that reported in randomised controlled trials (RCTs). The mOS of the chemotherapy-treated patients was slightly shorter compared with the results from RCTs and reflects the unselected population in this study. During the last decade, a larger fraction of patients received anticancer treatment, but the BSC group was still large and showed extremely poor OS.
Authors: Katsuhiko Mitachi; Rita G Kansal; Kirk E Hevener; Cody D Gillman; Syed M Hussain; Hyun Gi Yun; Gustavo A Miranda-Carboni; Evan S Glazer; William M Clemons; Michio Kurosu Journal: J Med Chem Date: 2020-09-18 Impact factor: 7.446
Authors: Fleur van der Sijde; Jacob L van Dam; Bas Groot Koerkamp; Brigitte C M Haberkorn; Marjolein Y V Homs; Daniëlle Mathijssen; Marc G Besselink; Johanna W Wilmink; Casper H J van Eijck Journal: J Oncol Date: 2022-07-07 Impact factor: 4.501
Authors: Linda A Rasmussen; Line F Virgilsen; Claus W Fristrup; Peter Vedsted; Henry Jensen Journal: Scand J Prim Health Care Date: 2022-04-29 Impact factor: 3.147